Morrisville, United States
SAGA Diagnostics, founded in 2016, is making significant strides in the biotechnology industry by focusing on personalized cancer medicine. Their unique approach centers on molecular genetic analyses of circulating tumor DNA and tissue biopsies, aiming to revolutionize the early detection of molecular residual disease (MRD).
Operating out of the United States, SAGA Diagnostics has positioned itself as a key player in cancer diagnostics. The company's tagline, "Redefining the early detection of molecular residual disease," underscores its commitment to advancing disease monitoring techniques.
In its quest for innovation, SAGA Diagnostics secured a substantial €10.50M Series A investment on 01 June 2021. This funding round was backed by notable investors including Segulah Medical Acceleration, Hadean Ventures, and Sciety, highlighting strong confidence in the company's growth potential from the investment community.
-logo.jpg "Foresight Diagnostics (a Natera company)"){kind=logo}
DiaCarta, Inc.
Predicine
